MLEC vs PGEN vs FATE vs RKDA vs CRSP

For growth investors, Moolec Science S.

A. (MLEC) is the stronger pick with 58. 3% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Analysts rate Precigen, Inc. (PGEN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Moolec Science S.

A. (MLEC) delivered a total return of -8. 0%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Moolec Science S.

A. (MLEC) is the lower-risk stock at 0. 76β versus Fate Therapeutics, Inc. 's 1. 99β — meaning FATE is approximately 160% more volatile than MLEC relative to the S&P 500. On balance sheet safety, Precigen, Inc. (PGEN) carries a lower debt/equity ratio of 14% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Moolec Science S.

A. (MLEC) is pulling ahead at 58. 3% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -89. 8% for Moolec Science S. A.. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Moolec Science S.

A. (MLEC) is the more profitable company, earning -33. 4% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps -33. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLEC leads at -3. 1% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — RKDA leads at 36. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Moolec Science S.

A. (MLEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 76)). Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLEC: -9. 3%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MLEC (Healthcare) and PGEN (Healthcare) and FATE (Healthcare) and RKDA (Basic Materials) and CRSP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MLEC is a small-cap high-growth stock; PGEN is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock; RKDA is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.